131 related articles for article (PubMed ID: 33124144)
1. Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children.
Freguja R; Bamford A; Zanchetta M; Del Bianco P; Giaquinto C; Harper L; Dalzini A; Cressey TR; Compagnucci A; Saidi Y; Riault Y; Ford D; Gibb D; Klein N; De Rossi A;
HIV Med; 2021 Mar; 22(3):172-184. PubMed ID: 33124144
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.
Bunupuradah T; Duong T; Compagnucci A; McMaster P; Bernardi S; Kanjanavanit S; Rampon O; Faye A; Saïdi Y; Riault Y; De Rossi A; Klein N; Ananworanich J; Gibb D;
AIDS; 2013 Feb; 27(4):579-89. PubMed ID: 23135172
[TBL] [Abstract][Full Text] [Related]
3. Response to planned treatment interruptions in HIV infection varies across childhood.
Paediatric European Network for Treatment of AIDS
AIDS; 2010 Jan; 24(2):231-41. PubMed ID: 20010073
[TBL] [Abstract][Full Text] [Related]
4. The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
Klein N; Sefe D; Mosconi I; Zanchetta M; Castro H; Jacobsen M; Jones H; Bernardi S; Pillay D; Giaquinto C; Walker AS; Gibb DM; De Rossi A;
PLoS One; 2013; 8(10):e76582. PubMed ID: 24194841
[TBL] [Abstract][Full Text] [Related]
5. Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection.
Sandgaard KS; Margetts B; Attenborough T; Gkouleli T; Adams S; Holm M; Gibb D; Gibbons D; Giaquinto C; De Rossi A; Bamford A; Palma P; Chain B; Gkazi AS; Klein N
Front Immunol; 2021; 12():643189. PubMed ID: 34475868
[TBL] [Abstract][Full Text] [Related]
6. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
7. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption.
Ananworanich J; Melvin D; Amador JT; Childs T; Medin G; Boscolo V; Compagnucci A; Kanjanavanit S; Montero S; Gibb DM;
AIDS; 2016 Apr; 30(7):1075-81. PubMed ID: 26730569
[TBL] [Abstract][Full Text] [Related]
8. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients.
Legrand FA; Abadi J; Jordan KA; Davenport MP; Deeks SG; Fennelly GJ; Wiznia AA; Nixon DF; Rosenberg MG
AIDS; 2005 Oct; 19(15):1575-85. PubMed ID: 16184026
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
10. Evolution of mitochondrial DNA content after planned interruption of HAART in HIV-infected pediatric patients.
Noguera A; Morén C; Rovira N; Sànchez E; Garrabou G; Nicolàs M; Muñoz-Almagro C; Cardellach F; Miró O; Fortuny C
AIDS Res Hum Retroviruses; 2010 Sep; 26(9):1015-8. PubMed ID: 20707732
[TBL] [Abstract][Full Text] [Related]
11. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children.
Mulu A; Liebert UG; Maier M
BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
[TBL] [Abstract][Full Text] [Related]
13. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
[TBL] [Abstract][Full Text] [Related]
14. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
15. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
Turkova A; Moore CL; Butler K; Compagnucci A; Saïdi Y; Musiime V; Nanduudu A; Kaudha E; Cressey TR; Chalermpantmetagul S; Scott K; Harper L; Montero S; Riault Y; Bunupuradah T; Volokha A; Flynn PM; Bologna R; Ramos Amador JT; Welch SB; Nastouli E; Klein N; Giaquinto C; Ford D; Babiker A; Gibb DM;
PLoS One; 2018; 13(4):e0196239. PubMed ID: 29684092
[TBL] [Abstract][Full Text] [Related]
16. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
17. Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.
Sued O; Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Claramonte X; Plana M; Tuset M; Pumarola T; Gallart T; Gatell JM; Miró JM
PLoS One; 2015; 10(7):e0131651. PubMed ID: 26186440
[TBL] [Abstract][Full Text] [Related]
18. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
Pai NP; Lawrence J; Reingold AL; Tulsky JP
Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006148. PubMed ID: 16856117
[TBL] [Abstract][Full Text] [Related]
19. Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.
Wamalwa D; Benki-Nugent S; Langat A; Tapia K; Ngugi E; Moraa H; Maleche-Obimbo E; Otieno V; Inwani I; Richardson BA; Chohan B; Overbaugh J; John-Stewart GC
AIDS; 2016 Sep; 30(15):2303-13. PubMed ID: 27177316
[TBL] [Abstract][Full Text] [Related]
20. Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.
Samri A; Goodall R; Burton C; Imami N; Pantaleo G; Kelleher A; Poli G; Gotch F; Autran B
Antivir Ther; 2007; 12(4):553-8. PubMed ID: 17668564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
